Clinical evaluation observes uncertain mortality benefits of hyperbaric oxygen therapy in necrotizing soft-tissue infections, highlighting persistent therapeutic controversy.
Necrotizing soft-tissue infection (NSTI) is a rare and serious disease with high morbidity and mortality. Standard therapeutic concepts have included urgent surgical intervention, broad-spectrum antibiotic treatment, and intensive care. Hyperbaric oxygen therapy (HBOT) is used as adjuvant therapy in some centers, but its benefits remain controversial.
No takes yet. Share an insight, caveat, or question.
Chiang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: